With 14 new gene therapy approvals in the last 18 months, billion-dollar collaborations, and the development of treatments for more common conditions, the gene therapy field is rapidly gaining momentum and broadening its scope beyond rare diseases. The new and improved 8th Gene Therapy Development Summit, formerly known as the Gene Therapy for Rare Disorders Summit, united senior leaders from the likes of Pfizer, REGENXBIO, Vertex, Vivet Therapeutics, Carbon Biosciences, Beam Therapeutics, and the FDA to tackle the field’s biggest challenges of achieving genuine scalability and accessibility to meet growing patient demand.

This unique opportunity provided attendees full visibility of cutting-edge developments from translation through to commercialization, gaining full competitor insight to benchmark novel approaches and inform and fast-track their gene therapy through the clinic, expanding their patient reach.